Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug855 | Caring Contacts Wiki | 1.00 |
| drug3893 | TRV027 Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
To determine whether the coagulopathy associated with COVID-19 infection is driven by overactivation of the renin angiotensin system (RAS)
Description: Mean change from baseline D-dimer at day 8 following administration of TRV027 or placebo.
Measure: Coagulopathy associated with COVID-19 Time: Day 1 and Day 8Description: Absolute D-Dimer - (Fibrin Equivalent units)
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, 5 and Day 8Description: platelet count (E9 /L)
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: aPTT (Activated Partial Thromboplastin time) - seconds
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: INR - (calculated as a ratio from aPTT)
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: fibrinogen (g/L)
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: Ferritin Ug/mL
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: Plasma Renin Mass and activity (ng/ml/h)
Measure: Markers of dysregulation of RAS Time: Day 3, Day 5 and Day 8Description: Total bilirubin (umol/L)
Measure: Markers of Haemolysis/inflammation Time: Day 1, 3, Day 5 and Day 8Description: LDH u/L
Measure: Markers of Haemolysis/Inflammation Time: Day 3, Day 5 and Day 8Description: Haptoglobin g/L
Measure: Markers of Haemolysis/inflammation Time: Day 1, 3, Day 5 and Day 8Description: Pro-calcitonin ug/L
Measure: Markers of Inflammation (bacterial sepsis) Time: day 1, 3, 5 and 8Description: Creatinine (umol/L)
Measure: Markers of organ dysregulation - kidney Time: Day 1, 3, Day 5 and Day 8Description: BNP (B-type natriuetic Peptide) ng/L
Measure: Markers of dysregulation of cardiovascular system Time: Day 1, 3, Day 5 and Day 8Description: Troponin ng/L
Measure: Markers of dysregulation of cardiovascular system Time: Day 1, 3, Day 5 and Day 8Description: glucose mmol/L
Measure: marker of dysregulation of endocrine system Time: Day 1, 3, Day 5 and Day 8Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports